# A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile

> **NCT02702388** · PHASE2 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 241 (actual)

## Conditions studied

- Thyroid Cancer

## Interventions

- **DRUG:** Lenvatinib
- **DRUG:** Lenvatinib matching placebo

## Key facts

- **NCT ID:** NCT02702388
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-08
- **Primary completion:** 2019-12-12
- **Final completion:** 2020-09-10
- **Target enrollment:** 241 (ACTUAL)
- **Last updated:** 2021-11-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02702388

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02702388, "A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02702388. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*